Jiangsu Genscend Biopharmaceutical Co., Ltd

Primary Study Objectives: 1) To verify the similarity of efficacy between GS101 injection and dupilumab injection (Dapixto®) in treating patients with moderate to severe atopic dermatitis. Secondary Study Objectives: 1) To evaluate the efficacy of GS101 injection and dupilumab injection (Dapixto®) in patients with moderate to severe atopic dermatitis based on secondary efficacy endpoints. 2) To evaluate the safety and tolerability of GS101 injection and dupilumab injection (Dapixto®) in patients with moderate to severe atopic dermatitis. 3) To evaluate the immunogenicity of GS101 injection and dupilumab injection (Dapixto®) in patients with moderate to severe atopic dermatitis. 4) To evaluate the population pharmacokinetic (PopPK) characteristics of GS101 injection and dupilumab injection (Dapixto®) in patients with moderate to severe atopic dermatitis.